Fierce Biotech

Inovio trims team as trouble brews at FDA for rare disease candidate

Inovio Pharmaceuticals has laid off staff and prioritized programs to focus on its lead rare disease candidate, which is ...
Fierce Biotech

Disc lays off 20% of employees to steady ship after FDA rejection of rare disease drug

Disc Medicine is laying off a fifth of its workforce as the biotech reels from the FDA’s rejection of its rare blood disease candidate. | Disc Medicine is laying off a fifth of its workforce as the ...
BioPharma Dive

Evotec, Vistagen lay off staff; Immutep shares collapse on study failure

Evotec will cut 800 employees in its second layoff round since 2024. Elsewhere, Ultragenyx got a needed win and a twice-rejected cell therapy is getting an audience at the FDA.

Disc Medicine to Cut 20% of Workforce After Treatment Fails to Get Accelerated FDA Approval

Disc Medicine is laying off about 20% of its workforce after the Food and Drug Administration denied its application for accelerated approval of its bitopertin treatment.
The Business Journals

Watertown biotech cuts 20% of staff after FDA rejects rare disease drug

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Disc Medicine had prepared a ...